Form4insider filings, from the source

SEC Form 4 · accession 0001298709-26-000011

Krystal Biotech, Inc. · KRYS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Krish S Krishnan
Officer — President and CEO · Director · 10% Owner
Period of report
Sep 4, 2026
Accepted (ET)
Sep 4, 2026 · 7:14 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001711279

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2,F3Sep 4, 2026S520$354.54D1,372,023D
Common StockF4Sep 4, 2026S2,029$355.5719D1,369,994D
Common StockF5Sep 4, 2026S3,297$356.3687D1,366,697D
Common StockF6Sep 4, 2026S3,981$357.5738D1,362,716D
Common StockF7Sep 4, 2026S3,143$358.4182D1,359,573D
Common StockF8Sep 4, 2026S3,357$359.3861D1,356,216D
Common StockF9Sep 4, 2026S2,266$360.463D1,353,950D
Common StockF10Sep 4, 2026S1,214$361.6091D1,352,736D
Common StockF11Sep 4, 2026S2,010$362.6504D1,350,726D
Common StockF12Sep 4, 2026S573$363.3424D1,350,153D
Common StockF13Sep 4, 2026S1,358$364.4794D1,348,795D
Common StockF14Sep 4, 2026S847$365.4163D1,347,948D
Common StockF15Sep 4, 2026S405$366.5567D1,347,543D
Common StockF16holding———90,000IBy SMK Trust FBO KSK
Common StockF17holding———77,710IBy Krish Srinivas Krishnan Trust
Common StockF18holding———50,000IBy Krishnan Family Trust

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses